Levormeloxifene

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Levormeloxifene
Levormeloxifene.svg
Clinical data
Synonyms Levomeloxifene; 6720-CDRI; NNC-460020
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C30H35NO3
Molar mass 457.604 g/mol
3D model (JSmol)
 NoYesY (what is this?)  (verify)

Levormeloxifene (INN; developmental code names 6720-CDRI, NNC-460020) is a selective estrogen receptor modulator (SERM) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed.[1] The development was stopped because of a high incidence of gynecological side effects during clinical trials.[2] Levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive.

See also[edit]

References[edit]

  1. ^ http://adisinsight.springer.com/drugs/800000737
  2. ^ Ravn P, Nielsen TF, Christiansen C (2006). "What can be learned from the levormeloxifene experience?". Acta Obstet Gynecol Scand. 85 (2): 135–42. PMID 16532904. 

External links[edit]